Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest.

Gargiulo, Giuseppe; Valgimigli, Marco; Sunnaker, Mikael; Vranckx, Pascal; Frigoli, Enrico; Leonardi, Sergio; Spirito, Alessandro; Gragnano, Felice; Manavifar, Negar; Galea, Roberto; De Caterina, Alberto R; Calabrò, Paolo; Esposito, Giovanni; Windecker, Stephan; Hunziker Munsch, Lukas (2020). Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. Revista española de cardiología (English ed.), 73(11), pp. 893-901. Elsevier 10.1016/j.rec.2020.01.005

Text Gargiulo_RevEspCardiol_EnglEd__2020.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (399kB) | Request a copy

INTRODUCTION AND OBJECTIVES

Patients who are vulnerable to hemodynamic or electrical disorders (VP) are often excluded from clinical trials and data on the optimal access-site or antithrombotic treatment are limited. We assessed outcomes of transradial vs transfemoral access and bivalirudin vs unfractionated heparin (UFH) in VP with acute coronary syndrome undergoing invasive management.

METHODS

The MATRIX trial randomized 8404 patients to radial or femoral access and 7213 patients to bivalirudin or UFH. Among them, 934 (11.1%) were deemed VP due to advanced Killip class (n = 808), cardiac arrest (n = 168), or both (n = 42). The 30-day coprimary outcomes were major adverse cardiovascular and cerebrovascular events (MACE: death, myocardial infarction, or stroke) and net adverse clinical events (NACE: MACE or major bleeding).

RESULTS

MACE and NACE were similarly reduced with radial vs femoral access in VP and non-VP. Transradial access was also associated with consistent relative benefits in all-cause and cardiovascular mortality or Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding with greater absolute benefits in VP. The effects of bivalirudin vs UFH on MACE and NACE were consistent in VP and non-VP. Bivalirudin was associated with lower all-cause and cardiovascular mortality in VP but not in non-VP, with borderline interaction testing. Bivalirudin reduced bleeding in both VP and non-VP with a larger absolute benefit in VP.

CONCLUSIONS

In acute coronary syndrome patients undergoing invasive management, the effects of randomized treatments were consistent in VP and non-VP, but absolute risk reduction with radial access and bivalirudin were greater in VP, with a 5- to 10-fold lower number needed to treat for benefits. Trial registry number: NCT01433627.

Interest & Impact

Downloads

4 since deposited on 18 Mar 2020
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item